R
Roger Stupp
Researcher at Northwestern University
Publications - 463
Citations - 73077
Roger Stupp is an academic researcher from Northwestern University. The author has contributed to research in topics: Temozolomide & Glioma. The author has an hindex of 93, co-authored 430 publications receiving 63025 citations. Previous affiliations of Roger Stupp include Merck & Co. & University of St. Gallen.
Papers
More filters
Journal ArticleDOI
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert,Meihua Wang,Kenneth Aldape,Roger Stupp,Monika E. Hegi,Kurt A. Jaeckle,Terri S. Armstrong,Terri S. Armstrong,Jeffrey S. Wefel,Minhee Won,Deborah T. Blumenthal,Anita Mahajan,Christopher J. Schultz,Sara Erridge,Brigitta G. Baumert,Kristen I. Hopkins,Tzahala Tzuk-Shina,Paul D. Brown,Arnab Chakravarti,Walter J. Curran,Minesh P. Mehta +20 more
TL;DR: This study did not demonstrate improved efficacy for DD temozolomide for newly diagnosed GBM, regardless of methylation status, but it did confirm the prognostic significance of MGMT methylation.
Journal ArticleDOI
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
Michael Weller,Martin J. van den Bent,Jörg C. Tonn,Roger Stupp,Matthias Preusser,Elizabeth Cohen-Jonathan-Moyal,Roger Henriksson,Emilie Le Rhun,Carmen Balana,Olivier Chinot,Martin Bendszus,Jaap C. Reijneveld,F. Dhermain,Pim J. French,Christine Marosi,Colin Watts,Ingela Oberg,Geoffrey J. Pilkington,Brigitta G. Baumert,Martin J.B. Taphoorn,Monika E. Hegi,Manfred Westphal,Guido Reifenberger,Riccardo Soffietti,Wolfgang Wick,Wolfgang Wick +25 more
TL;DR: The European Association for Neuro-Oncology guideline provides recommendations for the clinical care of adult patients with astrocytic and oligodendroglial gliomas, including glioblastomas, based on the 2016 WHO classification of tumours of the central nervous system and on scientific developments since the 2014 guideline.
Journal ArticleDOI
Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide
Monika E. Hegi,Annie Claire Diserens,Sophie Godard,Pierre-Yves Dietrich,Luca Regli,Sandrine Ostermann,Philippe Otten,Guy van Melle,Nicolas de Tribolet,Nicolas de Tribolet,Roger Stupp +10 more
TL;DR: The association of the epigenetic inactivation of the DNA repair gene MGMT with better outcome in this homogenous cohort may have important implications for the design of future trials and supports efforts to deplete MGMT by O-6-benzylguanine, a noncytotoxic substrate of this enzyme.
Journal ArticleDOI
Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity
Monika E. Hegi,Lili Liu,James G. Herman,Roger Stupp,Wolfgang Wick,Michael Weller,Minesh P. Mehta,Mark R. Gilbert +7 more
TL;DR: The data supporting MGMT as a major mechanism of chemotherapy resistance in malignant gliomas is reviewed and ongoing studies that are testing resistance-modulating strategies are described.
Journal ArticleDOI
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Michael Weller,Roger Stupp,Guido Reifenberger,Alba A. Brandes,Martin J. van den Bent,Wolfgang Wick,Monika E. Hegi +6 more
TL;DR: The prognostic and predictive value of MGMT silencing is critically discussed, reviewing trials in which patients with different types of glioma were treated with various chemotherapy schedules, either upfront or at recurrence.